Exact Mass: 342.2107
Exact Mass Matches: 342.2107
Found 287 metabolites which its exact mass value is equals to given mass value 342.2107,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Megestrol
G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03A - Hormonal contraceptives for systemic use > G03AC - Progestogens G - Genito urinary system and sex hormones > G03 - Sex hormones and modulators of the genital system > G03D - Progestogens > G03DB - Pregnadien derivatives L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02A - Hormones and related agents > L02AB - Progestogens C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents D000970 - Antineoplastic Agents
2alpha-Methyl-11-oxoprogesterone
E-64d
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid
2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid is found in nuts. 2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid is a minor constituent of cashew nut shel D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates
Guggulsterone
Guggulsterone is an ingredient in many nutritional supplements. Guggulsterone is a plant sterol derived from the gum resin (guggulu) of the tree Commiphora mukul. This sterol can inhibit NF-κB activation and downregulate the expression of inflammatory gene products such as COX-2 and MMP-9, which are major players in the development of arthritis. Guggulsterone also can suppress osteoclastogenesis induced by RANKL (receptor activator of NF-κB ligand), a bone-resorbing cytokine. The anti-inflammatory activity of C. mukul (guggul) has been compared with that of NSAIDs, namely phenylbutazone and ibuprofen. Guggulsterone is used to treat obesity, diabetes, hyperlipidemia, atherosclerosis, and osteoarthritis, and has been recently shown to antagonize the farnesoid X receptor and decrease the expression of bile acid-activated genes. It modulates activation of NF-kappaB, which has been closely linked with inflammatory diseases affected by guggulsterone. (PMID: 17475558, 15322087) [HMDB] Guggulsterone is an ingredient in many nutritional supplements. Guggulsterone is a plant sterol derived from the gum resin (guggulu) of the tree Commiphora mukul. This sterol can inhibit NF-κB activation and downregulate the expression of inflammatory gene products such as COX-2 and MMP-9, which are major players in the development of arthritis. Guggulsterone also can suppress osteoclastogenesis induced by RANKL (receptor activator of NF-κB ligand), a bone-resorbing cytokine. The anti-inflammatory activity of C. mukul (guggul) has been compared with that of NSAIDs, namely phenylbutazone and ibuprofen. Guggulsterone is used to treat obesity, diabetes, hyperlipidemia, atherosclerosis, and osteoarthritis, and has been recently shown to antagonize the farnesoid X receptor and decrease the expression of bile acid-activated genes. It modulates activation of NF-kappaB, which has been closely linked with inflammatory diseases affected by guggulsterone. (PMID: 17475558, 15322087).
2,3-Dinor-TXB2
Fatty Acyl-Eicosanoid - metabolite of thromboxane. Found to be excreted via urinary tract at a higher level in diabetic rats. A study demonstrates that thromboxane as well as prostacyclin biosynthesis is increased in 2 murine models of atherogenesis and is secondary to increased in vivo platelet activation. Assessment of their generation in these models may afford the basis for future studies on the functional role of these eicosanoids in the evolution and progression of atherosclerosisThromboxanes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. Fatty Acyl-Eicosanoid - metabolite of thromboxane. Found to be excreted via urinary tract at a higher level in diabetic rats. A study demonstrates that thromboxane as well as prostacyclin biosynthesis is increased in 2 murine models of atherogenesis and is secondary to increased in vivo platelet activation. Assessment of their generation in these models may afford the basis for future studies on the functional role of these eicosanoids in the evolution and progression of atherosclerosis
(-)-11-Hydroxy-9,15,16-trioxooctadecanoic acid
(-)-11-Hydroxy-9,15,16-trioxooctadecanoic acid is found in fruits. (-)-11-Hydroxy-9,15,16-trioxooctadecanoic acid is isolated from the seeds of Sambucus nigra (elderberry). Isolated from the seeds of Sambucus nigra (elderberry). (-)-11-Hydroxy-9,15,16-trioxooctadecanoic acid is found in fruits.
2,3-Dinor-6-keto-prostaglandin F1 a
2,3-dinor-6-keto-prostaglandin F1 alpha is a major urinary prostacyclin metabolite, and is significantly higher in 9 patients with severe atherosclerosis and evidence of platelet activation. Prostacyclin is a potent vasodilator and platelet inhibitor produced by vascular endothelium. Endogenous production of prostacyclin under physiologic conditions is extremely low, far below the capacity of vascular tissue to generate this substance in response to stimulation in vitro. This may reflect a low frequency or intensity of stimulation of prostacyclin production. PGI2 synthase (PGIS), a catalyst of PGI2 formation from prostaglandin H2, is widely distributed and predominantly found in vascular endothelial and smooth muscle cells. PGI2 plays an important cardioprotective role increasingly appreciated in recent years in light of adverse effects of COX-2 inhibitors in clinical trials. This cardioprotection is thought to be mediated, in part, by prostacyclin inhibition of platelet aggregation. Multiple lines of evidence suggest that prostacyclin additionally protects from cardiovascular disease by pleiotropic effects on vascular smooth muscle. PGI2 inhibits proliferation of cultured vascular SMCs by inhibiting cell cycle progression from G1 to S phase. (PMID: 6231483, 7000774, 6231483, 16303599, 16533160, 17073611, 17164138)Prostaglandins are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 2,3-dinor-6-keto-prostaglandin F1 alpha is a major urinary prostacyclin metabolite, and is significantly higher in 9 patients with severe atherosclerosis and evidence of platelet activation. Prostacyclin is a potent vasodilator and platelet inhibitor produced by vascular endothelium. Endogenous production of prostacyclin under physiologic conditions is extremely low, far below the capacity of vascular tissue to generate this substance in response to stimulation in vitro. This may reflect a low frequency or intensity of stimulation of prostacyclin production. PGI2 synthase (PGIS), a catalyst of PGI2 formation from prostaglandin H2, is widely distributed and predominantly found in vascular endothelial and smooth muscle cells. PGI2 plays an important cardioprotective role increasingly appreciated in recent years in light of adverse effects of COX-2 inhibitors in clinical trials. This cardioprotection is thought to be mediated, in part, by prostacyclin inhibition of platelet aggregation. Multiple lines of evidence suggest that prostacyclin additionally protects from cardiovascular disease by pleiotropic effects on vascular smooth muscle. PGI2 inhibits proliferation of cultured vascular SMCs by inhibiting cell cycle progression from G1 to S phase. (PMID: 6231483, 7000774, 6231483, 16303599, 16533160, 17073611, 17164138)
17-Hydroxymethylethisterone
17-Hydroxymethylethisterone is a metabolite of danazol. Danazol is a derivative of the synthetic steroid ethisterone, a modified testosterone. Also known as 17alpha-ethinyl testosterone. Before becoming available as a generic drug, Danazol was marketed as Danocrine in the United States. It was approved by the U.S. Food and Drug Administration (FDA) as the first drug to specifically treat endometriosis in the early 1970s. Although effective for endometriosis, its use is limited by its masculinizing side-effects. (Wikipedia)
Monic acid
Monic acid is a metabolite of mupirocin. Mupirocin (Bactroban or Centany) is an antibiotic originally isolated from Pseudomonas fluorescens NCIMB 10586, developed by Beecham. Mupirocin is bacteriostatic at low concentrations and bactericidal at high concentrations. It is used topically and is effective against Gram-positive bacteria, including MRSA. Mupirocin is a mixture of several pseudomonic acids, with pseudomonic acid A (PA-A) constituting greater than 90\\% of the mixture. (Wikipedia) No systemic absorption of mupirocin or its major metabolite, monic acid, has been detected in short courses of topical administration to healthy volunteers or to patients with epidermolysis bullosa after prolonged courses of therapy with Bactroban ointment. (PMID: 2112164)
2,3-dinor-6-oxoprostaglandin F1alpha
2,3-dinor-6-oxoprostaglandin F1alpha is also known as 2,3-Dinor-6-keto-PGF1alpha or 2,3-DKPGF1alpha. 2,3-dinor-6-oxoprostaglandin F1alpha is considered to be practically insoluble (in water) and acidic. 2,3-dinor-6-oxoprostaglandin F1alpha can be synthesized from prostaglandin F1alpha. 2,3-dinor-6-oxoprostaglandin F1alpha can be synthesized into 19-hydroxy-2,3-dinor-6-oxoprostaglandin F1alpha. 2,3-dinor-6-oxoprostaglandin F1alpha is an eicosanoid lipid molecule
14-oxo-DoHE(1-)
14-oxo-DoHE(1-) is also known as 14-oxo-(4Z,7Z,10Z,12E,16Z,19Z)-Docosahexaenoate. 14-oxo-DoHE(1-) is considered to be practically insoluble (in water) and acidic
Pregn-4-en-20-yn-3-one, 17-hydroxy-2-(hydroxymethyl)-, (2alpha,17alpha)-
2,3-Dinor-6,15-dioxo-13,14-dihydroprostaglandin F1alpha
(Z)-5-((2R,3S,4S,6R)-4,6-Dihydroxy-2-((S,E)-3-hydroxyoct-1-enyl)tetrahydro-2H-pyran-3-yl)pent-3-enoic acid
5-[(1S,2S,3S,5R)-3,5-Dihydroxy-2-[(E,3R)-3-hydroxyoct-1-enyl]cyclopentyl]-4-oxopentanoic acid
2-Hydroxy-6-pentadeca-8,11,14-trienyl benzoic acid
Aloxistatin
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
Prostaglandin F-main urinary metabolite
Trimegestone
12-HYDROXY-13-(HYDROXYMETHYL)-3,5,7-TRIMETHYLTETRADECA-2,4-DIENEDIOIC ACID
Ethyl 3-(3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl)-2-oxiranecarboxylate
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015853 - Cysteine Proteinase Inhibitors D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
(E, E)-form/2, 5-Dihydroxy-3-(3, 7, 11-trimethyl-2, 6, 10-dodecatrienyl)benzaldehyde|3-farnesyl-2,5-dihydroxybenzaldehyde
20,21,22,23,24,25,26,27-octanorcucurbit-5-ene-3,7,16-trione|octanorcucurbitacin B
20,21,22,23,24,25,26,27-octanorcucurbit-5-ene-3,7,17-trione|octanorcucurbitacin A
10-acetoxy-9-hydroxyamphilecta-8,10,12,14-tetraene
2-(7-hydroxy-4,8-dimethyl-3E,8-nonadienyl)-5-hydroxy-2,7-dimethyl-2H-chromene|daurichromene A
5-methyl-2-[(2E,7Z)-3,7,11-trimethyl-2,7-dodecadien-9-onyl]benzo-1,4-quinone
2-[1,3,5,7-Tetramethyl-8-ethylbicyclo[4.2.0]octa-2,4-diene-7-yl]-3,5-dimethyl-6-methoxy-4H-pyran-4-one
5-methyl-2-[(2E,6E)-3,7,11-trimethyl-2,6-dodecadien-9-onyl]benzo-1,4-quinone
Tricyclo[6.3.1.0(1,5)]dodecan-9-ol, 2-benzoyloxy-4,4,8-trimethyl-
(4S,5S)-4-(5-carboxylundecyl)-1-oxo-tetrahydrofuran-4-carboxylic acid methyl ester|spiculisporic acid C
2-(1-carboxydodecyl)-5-oxooxolane-2-carboxylic acid
2-(3-hydroxy-8-methyl-4-methyliden-7-nonaenyl)-5-hydroxy-2,7-dimethyl-2H-chromene|daurichromene B
7-oxo-20,21,22,23,24,25,26,27-octanor-14,18-cycloapotirucalla-1-en-3,4-olide|simaroubin E
2R-(9-hydroxy-4,8-dimethyl-3E,7E-nonadienyl)-5-hydroxy-2,7-dimethyl-2H-chromene|daurichromene D
2(R),3(S),4(S)-3,18-methylene-2alpha-acetoxyspongia-13(16),14-diene
12-Acetoxy-abieta-8,11,13-trien-7-on|12-acetoxy-abieta-8,11,13-trien-7-one|sugiol acetate|Sugiol-Acetat|Sugiolacetat
3-geranyl-4-hydroxy-5-(3,3-dimethylallyl)-benzoicacid|3-geranyl-4-hydroxy-5-(3,3-dimethylallyl)-benzoic acid|3-geranyl-4-hydroxy-5-(3-methyl-2-butenyl)benzoic acid|3-geranyl-4-hydroxy-5-(3?,3?-dimethylallyl)benzoic acid|5-geranyl-4-hydroxy-5-(3-methyl-2-butenyl)-benzoic acid|myrsinoic acid|myrsinoic acid A
2-(8-hydroxy-4,8-dimethyl-3E,6Z-nonadienyl)-5-hydroxy-2,7-dimethyl-2H-chromene|daurichromene C
5beta,19-epoxy-20,21,22,23,24,25,26,27-octanorcucurbit-6-ene-3,17-dione|octanorcucurbitacin C
(2E,4E)-12-hydroxy-13-(hydroxymethyl)-3,5,7-trimethyltetradeca-2,4-dienedioic acid
C22H30O3_2-Hydroxy-6-[(8Z,11Z)-8,11,14-pentadecatrien-1-yl]benzoic acid
(2E,4E)-12-hydroxy-13-(hydroxymethyl)-3,5,7-trimethyltetradeca-2,4-dienedioic acid
2-hydroxy-6-[(8Z,11Z)-pentadeca-8,11,14-trienyl]benzoic acid
(2E,4E)-12-hydroxy-13-(hydroxymethyl)-3,5,7-trimethyltetradeca-2,4-dienedioic acid [IIN-based on: CCMSLIB00000847643]
(2E,4E)-12-hydroxy-13-(hydroxymethyl)-3,5,7-trimethyltetradeca-2,4-dienedioic acid [IIN-based: Match]
2,3-Dinor-TXB2
4Z,7Z,10Z,13Z,15E,19Z-17-keto-docosapentaenoic acid
2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid
D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates
(6S,8S,9S,10R,11S,13S,14S,17S)-17-acetyl-11-hydroxy-6,10,13-trimethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one
Sensorcaine
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
3,4-dihydroxy-4-[(3E,6E)-tetradeca-3,6-dienoyl]oxybutanoic acid
ethenyl acetate,4-ethyl-2-methylideneoctanoic acid,prop-2-enoic acid
4-Ethyl-2,3-difluoro-4-(trans-4-propylcyclohexyl)-1,1-biphenyl
Trimegestone
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C389 - Oral Contraceptive
butyl 2-methylprop-2-enoate,ethyl prop-2-enoate,methyl 2-methylprop-2-enoate
{(3r,4r)-4-Methyl-3-[methyl(7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)amino]piperidin-1-Yl}(Pyrrolidin-1-Yl)methanone
Myrsinoic acid A
A monohydroxybenzoic acid that is 4-hydroxybenzoic acid substituted by a geranyl group at position 3 and a prenyl group at position 5. Isolated from Myrsine seguinii, it exhibits anti-inflammatory activity.
1-(1-Adamantylcarbonyl)-4-(2-fluorophenyl)piperazine
(8R,9S,13S,14S)-13-methyl-3-trimethylsilyloxy-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one
(4Z,7Z,10Z,12E,14E)-15-{(2S,3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,12,14-pentaenoic acid
(13S,14S)-epoxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid
An epoxy fatty acid consisting of (4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid having an epoxy group at the 13,14-position. An intermediate lipid in specialized proresolving mediators
2,3-Dinor-6,15-dioxo-13,14-dihydroprostaglandin F1alpha
(Z)-5-((2R,3S,4S,6R)-4,6-Dihydroxy-2-((S,E)-3-hydroxyoct-1-enyl)tetrahydro-2H-pyran-3-yl)pent-3-enoic acid
5-[(1S,2S,3S,5R)-3,5-Dihydroxy-2-[(E,3R)-3-hydroxyoct-1-enyl]cyclopentyl]-4-oxopentanoic acid
(E)-5-[3,5-dihydroxy-2-(8-hydroxy-3-oxooctyl)cyclopentyl]pent-3-enoic acid
12-Hydroxy-13-(hydroxymethyl)-3,5,7-trimethyl-2,4-tetradecadienedioic acid
(4Z,7Z,10Z,13Z,15E,19Z)-17-Oxodocosahexaenoic acid
An oxodocosahexaenoic acid that is (4Z,7Z,10Z,13Z,15E,19Z)-docosahexaenoic acid in which the oxo group is located at position 17. An intermediate of specialised proresolving mediators.
(4Z,7Z,10Z,14E,16Z,19Z)-13-Oxodocosahexaenoic acid
An oxodocosahexaenoic acid that is (4Z,7Z,10Z,14E,16Z,19Z)-docosahexaenoic acid in which the oxo group is located at position 13. An intermediate of specialised proresolving mediators.
omega-(3-Oxo-17-beta-hydroxy-4-androsten-17-alpha-yl) propionic acid lactone
14-oxo-DoHE
An oxo fatty acid that consists of (4Z,7Z,10Z,12E,16Z,19Z)-docosahexaenoic acid carrying a single oxo substituent at position 14.
(R)-4-(tert-Butyldiphenylsilyloxy)-3-methyl-1-butanol
(4Z,7Z,10Z,13Z)-15-{(3R)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-ylidene}pentadeca-4,7,10,13-tetraenoic acid
(9S,16S)-dihydroperoxy-(10E,12Z,14E)-octadecatrienoic acid
(4S,7R)-4-(phenylmethyl)-7-propan-2-yl-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
(4S,7S)-4-(phenylmethyl)-7-propan-2-yl-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
(5S,8S)-8-(phenylmethyl)-5-propan-2-yl-3-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-7-one
(4R,7R)-4-(phenylmethyl)-7-propan-2-yl-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
(4R,7S)-4-(phenylmethyl)-7-propan-2-yl-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
(5R,8R)-8-(phenylmethyl)-5-propan-2-yl-3-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-7-one
6beta,17-Dihydroxy-3,5-cyclo-5alpha,17alpha-pregn-20-ene-21-carboxylic acid, gamma-lactone
(4Z,7Z,10Z,13Z)-15-{(3S)-3-[(2Z)-pent-2-en-1-yl]oxiran-2-ylidene}pentadeca-4,7,10,13-tetraenoic acid
(17R)-17-ethynyl-17-hydroxy-2-(hydroxymethyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
(2R,8R,9S,10R,13S,14S)-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-3H-spiro[cyclopenta[a]phenanthrene-17,2-furan]-3,5(2H,4H)-dione
(10,13-Dimethyl-3-oxo-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl) propanoate
2-[(3-Hexoxy-2-hydroxypropoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
ethyl (2R,3R)-3-[[(2S)-4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate
2,3-dinor-6-oxoprostaglandin F1alpha
A prostanoid that is prostaglandin F1alpha lacking two methylenes in the carboxyalkyl chain and bearing an oxo group at the 6-position.
(4Z,8E,10Z,13Z,16Z,19Z)-7-oxodocosahexaenoic acid
A oxodocosahexaenoic acid that consists of (4Z,8E,10Z,13Z,16Z,19Z)-docosahexaenoic acid carrying an oxo substituent at position 7. An intermediate of specialised proresolving mediators.
(16S,17S)-epoxy-(4Z,7Z,10Z,12E,14E,19Z)-docosahexaenoic acid
An epoxy fatty acid consisting of (4Z,7Z,10Z,12E,14E,19Z)-docosahexaenoic acid having an epoxy group located at the 16,17-position. An intermediate lipid in specialized proresolving mediators.
2-(8-hydroxy-4,8-dimethylnona-3,6-dien-1-yl)-2,7-dimethylchromen-5-ol
3-{[(1r,4ar,8ar)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-4-hydroxybenzoic acid
(3as,3br,9as,9bs,11as)-3a,6,6,9b,11a-pentamethyl-2h,3h,3bh,8h,9h,9ah,10h,11h-cyclopenta[a]phenanthrene-1,4,7-trione
(3z,7e,11e,13r)-13-methoxy-3,7,11-trimethylbicyclo[12.2.2]octadeca-1(16),3,7,11,14,17-hexaene-15,17-diol
methyl 3-methoxy-4,7-dimethyl-9-(2-methylprop-1-en-1-yl)-5,6,6a,7,8,9-hexahydro-4h-phenalene-1-carboxylate
3-hydroxy-3-isopropyl-6,8a-dimethyl-1,2,3a,4,5,8-hexahydroazulen-4-yl benzoate
methyl 7-(acetyloxy)-3a-hydroxy-3-(hydroxymethyl)-1,1,3,5-tetramethyl-hexahydroindene-4-carboxylate
4-hydroxy-3-[(2z,6z)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]benzoic acid
13-methoxy-3,7,11-trimethylbicyclo[12.2.2]octadeca-1(16),3,7,11,14,17-hexaene-15,17-diol
(3r,3as,4s,8ar)-3-hydroxy-3-isopropyl-6,8a-dimethyl-1,2,3a,4,5,8-hexahydroazulen-4-yl benzoate
3-[(3e,6e,8r)-11-(furan-3-yl)-8-methoxy-4,8-dimethylundeca-3,6-dien-1-yl]furan
methyl (4r,6as,7s,9s)-3-methoxy-4,7-dimethyl-9-(2-methylprop-1-en-1-yl)-5,6,6a,7,8,9-hexahydro-4h-phenalene-1-carboxylate
3-[11-(furan-3-yl)-8-methoxy-4,8-dimethylundeca-3,6-dien-1-yl]furan
2,5-dihydroxy-3-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)benzaldehyde
(2e)-3-[(1s,3r,4r,7r,8r,11s)-3-[(2z)-but-2-en-2-yl]-4,6,8,10,11-pentamethyl-2-oxatricyclo[5.3.1.0⁴,¹¹]undeca-5,9-dien-8-yl]prop-2-enoic acid
4-hydroxy-3-(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)benzoic acid
3-[(4e,6s,8e)-11-(furan-3-yl)-6-methoxy-4,8-dimethylundeca-4,8-dien-1-yl]furan
(2e,4s)-4-[(2s,3s,4r,5s,6s,8r,9s,10r)-4,10-dihydroxy-3,5,8,9-tetramethyl-1,7-dioxaspiro[5.5]undecan-2-yl]pent-2-enoic acid
1-(2,5-dihydroxy-3-methylphenyl)-3,7,11-trimethyldodeca-2,6,10-trien-5-one
(1r,2s,5r,8s,9r)-9-hydroxy-4,4,8-trimethyltricyclo[6.3.1.0¹,⁵]dodecan-2-yl benzoate
anacardicacid d
{"Ingredient_id": "HBIN015966","Ingredient_name": "anacardicacid d","Alias": "NA","Ingredient_formula": "C22H30O3","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT14276","TCMID_id": "1130","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
